Kong Leopold, Kadam Rameshwar U, Giang Erick, Ruwona Tinashe B, Nieusma Travis, Culhane Jeffrey C, Stanfield Robyn L, Dawson Philip E, Wilson Ian A, Law Mansun
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
J Mol Biol. 2015 Aug 14;427(16):2617-28. doi: 10.1016/j.jmb.2015.06.012. Epub 2015 Jun 30.
Hepatitis C virus (HCV) is a positive-strand RNA virus within the Flaviviridae family. The viral "spike" of HCV is formed by two envelope glycoproteins, E1 and E2, which together mediate viral entry by engaging host receptors and undergoing conformational changes to facilitate membrane fusion. While E2 can be readily produced in the absence of E1, E1 cannot be expressed without E2 and few reagents, including monoclonal antibodies (mAbs), are available for study of this essential HCV glycoprotein. A human mAb to E1, IGH526, was previously reported to cross-neutralize different HCV isolates, and therefore, we sought to further characterize the IGH526 neutralizing epitope to obtain information for vaccine design. We found that mAb IGH526 bound to a discontinuous epitope, but with a major component corresponding to E1 residues 314-324. The crystal structure of IGH526 Fab with this E1 glycopeptide at 1.75Å resolution revealed that the antibody binds to one face of an α-helical peptide. Single mutations on the helix substantially lowered IGH526 binding but did not affect neutralization, indicating either that multiple mutations are required or that additional regions are recognized by the antibody in the context of the membrane-associated envelope oligomer. Molecular dynamics simulations indicate that the free peptide is flexible in solution, suggesting that it requires stabilization for use as a candidate vaccine immunogen.
丙型肝炎病毒(HCV)是黄病毒科中的一种正链RNA病毒。HCV的病毒“刺突”由两种包膜糖蛋白E1和E2形成,它们共同通过与宿主受体结合并经历构象变化以促进膜融合来介导病毒进入。虽然在没有E1的情况下E2可以很容易地产生,但没有E2时E1无法表达,并且包括单克隆抗体(mAb)在内的用于研究这种重要的HCV糖蛋白的试剂很少。先前报道了一种针对E1的人源单克隆抗体IGH526可交叉中和不同的HCV分离株,因此,我们试图进一步表征IGH526的中和表位,以获取疫苗设计的信息。我们发现单克隆抗体IGH526与一个不连续表位结合,但主要成分对应于E1的314 - 324位残基。IGH526 Fab与该E1糖肽的晶体结构在1.75Å分辨率下显示,该抗体与α - 螺旋肽的一个面结合。螺旋上的单个突变显著降低了IGH526的结合,但不影响中和作用,这表明要么需要多个突变,要么在膜相关包膜寡聚体的背景下抗体识别其他区域。分子动力学模拟表明,游离肽在溶液中是灵活的,这表明它需要稳定化才能用作候选疫苗免疫原。